01 FC:4021

Commissioner of Patents and Trademarks Box Assignment, Washington, D.C. 20231

REC(

200.00 0

11-05-2002



102272199

Form PTO-1595 Patent and Trademark Office

Our Ref.: 124-1

ease record the attached original documents or copy thereof.
2. Name and address of receiving party(ies):
Name: PSIMEDICA Limited
Internal Address:
Street Address: Malvern Hills Science Park, Geraldine
Road
City: Malvern, Worcestershire
State/Country: Great Britain
Zip: WR14 3SZ
Additional name/s & address/es attached? \(\subseteq \text{Yes} \subseteq \text{No} \)
tion date of the application is:
D. Datast No.(a)
B. Patent No(s).
(1) <u>6,322,895</u> (2)
$\begin{pmatrix} (2) \\ (3) \end{pmatrix}$
attached Yes No
6. Total number of applications & patents involved: 5
o. Total named of applications of patents in order
7. Total fee (37 CFR 3.41) \$ 200.00
Authorized to be charged to deposit account #14-1140
8. The Commissioner is hereby authorized to charge any
<u>deficiency</u> in the fee(s) filed, or asserted to be filed, or which
should have been filed herewith (or with any paper thereafter
filed in this application by this firm) to our Account No.
14-1140.
SE THIS SPACE
nation is true and correct and any attached copy is a true copy
DAR
VIII
October 29, 2002
Signature Date
iginal cover sheet, attachments, and document: [19]
iginal cover sheet, attachments, and document: [19]

Commissioner of Patents and Trademarks

Our Ref: 124-1

RECORDATION FORM COVER SHEET

PATENTS ONLY

Box Assignment, washington, D.C. 20231		
1. Name of conveying party(ies):		
2. Name: Street Address: City: State: Zip:	•	
 4. Application number(s) or patent number(s): A. Patent Application No(s). (4) 10/148,676 (5) (6) (7) (8) (9) 	B. Patent No(s). (4) (5) (6) (7) (8) (9)	

REEL: 013438 FRAME: 0707

I certify this to be a true copy

of the original.

Solicitor (Scotland)

Farnborough, Hants ASSIGNMENT OF INTELLECTUAL PROPERTY

THIS AGREEMENT is made on 1/7 MAXCH 2002 YBETWEEN QinetiQ Limited, a company registered in England with Registered No. 3796233 of 85 Buckingham Gate, London SW1E 6PD ("QinetiQ") and PSIMEDICA Limited, a company registered in England with Registered No. 4027099 whose registered office is at Malvern Hills Science Park, Geraldine Road, Malvern, Worcestershire WR14 3SZ ("PSL")

WHEREAS

- Α. Pursuant to a Technology Licence Agreement (as defined below) between PSL and the Secretary of State for Defence (acting through the Defence Evaluation and Research Agency), PSL has been granted an exclusive licence to use the Domain Name, Know-how, Patents and Trade Marks (as defined below);
- B. the Secretary of State for Defence has assigned the Intellectual Property (as defined in the Technology Licence Agreement to QinetiQ;
- pursuant to a novation agreement between PSL, the Secretary of State C. for Defence and QinetiQ dated 3rd October 2001, the exclusive licence granted to PSL by the Secretary of State for Defence under A. above has been novated as between PSL and QinetiQ; and
- D. pursuant to Clause 2.2 of the Technology Licence Agreement, QinetiQ has agreed to assign the Domain Name, Know-how, Patents and Trade Marks to PSL and PSL has agreed to accept assignment of the

65/n/270 -06/03/02

Domain Name, Know-how, Patents and Trade Marks on the terms and conditions of this Agreement.

NOW IT IS HEREBY AGREED as follows:

1. INTERPRETATION

be a true copy

certify this to

the original

Solicitor (Scot Farnborough,

1.1 In this Agreement where the context so admits the following expressions shall have the following meanings:

"Affiliate" means, in relation to either party, a subsidiary, holding company or any subsidiary of such holding company (as these terms are defined in Section 736 of the Companies Act 1985);

"DERA" means The Secretary of State for Defence acting through the Defence Evaluation and Research Agency whose head office is at Ively Road, Farnborough, Hampshire GU14 OLX;

"Domain Name" means the domain name listed in Schedule 3 hereof;

"Effective Date" means the date this Agreement is executed;

"Field" means the technical fields covered by the Patents and Know-how namely biological and/or biomedical and/or diagnostics and/or cosmetic applications of porous silicon and/or polysilicon on or in the human or animal body.

"Intellectual Property" means patents, supplementary protection certificates, petty patents, trade marks, trade names, service marks, design rights, database rights, domain names, rights in undisclosed confidential information,

2

(such as know-how, trade secrets, and inventions (whether patentable or not)), and other similar intellectual property rights (whether registered or not) and applications for such rights as may exist anywhere in the world.

"Know-How" means the QinetiQ-owned know-how, inventions and/or non-patent information of Dr L Canham and Dr R Aston, including all data and/or knowledge relating to the Technology as set out in Schedule 2 hereof;

"Patents" means those patents and patent applications short particulars of which are set forth in Schedule 1 hereof and any divisionals, re-issues, continuations, continuation-in-parts, or extensions thereto or supplementary protection certificates;

I certify this to be a true copy of the original.

✓ for at a frame of the original.

✓ for at a frame of the original or at

"Technology" means the technology relating to biocompatible silicon as claimed and disclosed in the Patents and Know-how and as developed over the past 20 man years at DERA; and

"Technology Licence Agreement" means the agreement between the parties dated 11 December 2000 between PSL and the Secretary of State for Defence (acting through the Defence Evaluation and Research Agency); and

"Trade Marks" means both the registered and unregistered trade marks and/or trade names listed in Schedule 4 hereof.

- 1.2 Clause headings are solely for ease of reference and do not form part of or affect the interpretation of this Agreement;
- 1.3 The Schedules referred to form part of this Agreement; and

I certify this to be a true copy of the original.

June 1: 15 4 0 --
Jonathan Trapp Solicitor (Scotland)
Farnborough, Hants

1.4 Where the context so admits or requires, words denoting the singular include the plural and vice versa and words denoting any gender include all genders.


2. ASSIGNMENT AND LICENCE BACK OF INTELLECTUAL PROPERTY

- 2.1 In consideration of the payment to QinetiQ by PSL of £1, QinetiQ does hereby assign with full title guarantee and free from charges, liens mortgages or other encumbrances of any kind, to hold unto PSL absolutely all its interest in and to:
 - (a) Patents;
 - (b) Know-how;
 - (c) Domain Name;
 - (d) Trade Marks; and
 - (e) all other the Intellectual Property subsisting in the subject matter of the rights set out in Schedules 1, 2, 3 and 4;

and the full and exclusive benefit thereof and rights, privileges and advantages associated with them, including:

- 2.1.1 the full right to apply for and obtain patents or other forms of protection in respect of all or any part of the Technology and/or the Know-how throughout the world;
- 2.1.2 the right to claim priority from the patent applications included with the Patents under the Paris Convention (as amended) when making such applications;
- 2.1.3 the right to file divisional, continuation and continuation-in-part applications in its own name in respect of subject matter described in the Patents; and

4



4 the right to recover, and take all such proceedings as may be necessary for the recovery of, damages or other forms of relief in respect of all infringements of rights in the Domain Name, Know-how, Patents or Trade Marks or any rights assigned under this Agreement whether taking place before or after the date of this Agreement but not such rights in relation to copyright prior to 1 July 2001.

netiQ hereby grants PSL an irrevocable exclusive royalty-free licence to use the copyright and related rights subsisting in the subject matter of the rights set out in Schedule 1, 2, 3 and 4.


- 2.3 PSL agrees to be responsible for any fees and costs associated with the recording of the assignment of the Patents, Trade Marks, Domain Names, including any costs at the Patent Office or any equivalent registry including any relevant domain name registry.
- QinetiQ agrees, at PSL's request and cost, to do and procure to be done all other acts and to execute and deliver all such further documents and instruments as shall be required to give full effect to the assignment under Clause 2.1 of this Agreement, or the recordal by PSL of this assignment including by signing any documents required by the Patent Office or other equivalent registry including any relevant domain name registry.
- 2.5 PSL agrees that the assignment by QINETIQ in respect of the Know-how and Patents shall be subject to QINETIQ's right to use the Know-how and Patents and all other the Intellectual Property subsisting in the subject matter of the rights set out in Schedules 1 and 2 as reasonably necessary to conduct research relating to other Intellectual Property rights owned, controlled or used by QINETIQ;
- 2.6 PSL hereby grants to QinetiQ, with the right to grant sub-licences only to the Secretary of State for Defence on similar terms, a royalty free irrevocable licence to use the Know-how and Patents and all other the Intellectual

Property subsisting in the subject matter of the rights set out in Schedules 1 and 2 for any defence-related non-commercial purposes;


2.7 Subject to Clauses 2.5 and 2.6, PSL hereby grants to QinetiQ an exclusive licence on fair and reasonable terms to be agreed to use and to sub-licence the use of the Know-how and Patents and all other the Intellectual Property subsisting in the subject matter of the rights set out in Schedules 1 and 2 for any purpose outside the Field.

3. TECHNOLOGY LICENCE AGREEMENT VARIATION

- In consideration of the sum of £1 to be paid by PSL, as from the Effective Date, QinetiQ and PSL agree that the terms of the Technology Licence Agreement shall be varied as of the date of this agreement as follows:
 - 3.1.1 Clauses 3.2 and 3.3 are hereby cancelled;
 - 3.1.2 Clause 4.2 is hereby cancelled;
 - 3.1.3 The whole of clause 6 is hereby cancelled;
 - 3.1.4 A new clause 6 is hereby added as follows:



PSL shall be responsible for all costs and duties relating to the prosecution, and maintenance of the Patents in all jurisdictions world-wide. Should PSL wish to not maintain a Patent within a particular jurisdictions, it shall notify QinetiQ 60 (sixty) days in advance of their decision. If QinetiQ wishes to have the Patents prosecuted or maintained in those jurisdictions QinetiQ shall have 60 (sixty) days from notification from PSL in which to provide written notice to PSL of its interest. PSL shall within 60 (sixty) days of notification from QinetiQ assign to QinetiQ for no additional cost, the right to apply prosecute, maintain the



national patents in those jurisdictions in QinetiQ 's name. QinetiQ shall in that event be the sole owner of those patents in those jurisdictions and shall be solely responsible for all costs and expenses relating to prosecution or maintenance of those patents.

6.2 As long as QinetiQ's share of the equity in PSL is above 25%, QinetiQ shall endeavour to offer to PSL intellectual property assistance and patenting services at its current rates of charge, unless such would introduce a conflict of interest."; and

3.1.5 Clause 12.1 is hereby cancelled;

all other provisions of the Technology Licence Agreement shall, to the extent that they are not inconsistent with the terms of this Agreement, continue on the same terms and conditions as stated in the Technology Licence Agreement.

4. GENERAL

- 4.1 All notices and other communications required or permitted to be given to either party under this Agreement shall be in writing and be delivered or transmitted to the intended recipient's address as specified above but in the case of QinetiQ to Director QinetiQ IP, G016, A4 Blg, QinetiQ Ltd, Cody Technology Park, Ively Road Farnborough,, GU14 0LX, UK, or such other address as either party may notify to the other from time to time. Any notice shall be treated as having been given when received if sent by telex or facsimile, and shall be deemed given on the expiry of 48 hours from sending if sent by ordinary first class post within the United Kingdom.
- 4.2 The failure of either party to enforce or to exercise, at any time or for any period of time, any term of or any right arising pursuant to this Agreement does not constitute, and shall not be construed as, a waiver of such term or

right and shall in no way affect that Party's right later to enforce or to exercise it.

- 4.3 The invalidity or unenforceability of any term of or any right arising pursuant to this Agreement shall in no way affect the remaining terms or rights.
- 4.4 The relationship of the parties is that of independent contractors dealing at arm's length and nothing in this Agreement shall be construed so as to constitute the parties as partners, joint venturers or co-owners or empower PSL to act for, bind on otherwise create or assume any obligation on behalf of QinetiQ.

I certify this to be a true copy of the original.

Solicitor (Scotland)

Farnborough, Hants

Each of the parties acknowledges that its authorised representative has read the terms of this Agreement and affirms that it contains all the terms agreed between them regarding the subject matter of this Agreement, incorporating by reference the Technology Licence Agreement, and supersedes any prior agreement, other than the surviving terms of the Technology Licence Agreement varied by Clause 3 of this Agreement, understanding or arrangement between them, whether oral or in writing. No representation, undertaking or promise shall be taken to have been given or be implied from anything said or written in negotiations between the parties prior to this Agreement except as expressly stated in this Agreement, incorporating by reference the terms of the Technology Licence Agreement, unless such representation, undertaking or promise was made fraudulently.

- 4.6 The construction, validity and performance of this Agreement shall be governed by the laws of England and the parties hereby submit to the exclusive jurisdiction of the English Courts.
- 4.7 No person who is not a party to this agreement other than the Secretary of State for Defence shall be entitled to rely on or to directly receive any benefit hereunder as a result of the Contracts (Rights of Third Parties) Act 1999.

I certify this to be a true copy
of the original. Jonathan Traff 15/4/02
Jonathan Trapp
Solicitor (Scotland)
Farnborough, Hants

DULY signed by authorised representatives of the parties:

SIGNED by HAL E. KEUTH /)

for and on behalf of

QinetiQ

SIGNED by [

for and on behalf of PSL

D.W. BRIHBECOMPE

I certify this to be a true copy of the original.

Jonathan Trapp

Jonathan Trapp

Solicitor (Scotland)

Farnborough, Hants



SCHEDULE 1

Patents


QinetiQ Ref	Title	Country	Application No	Filing date	Granted
01P 2292	Bioactive Material	GB/P1	9515956.2	3/8/95	
		GB/P2	9524242.6	28/11/95)
		GB/P3	9611437.6	31/5/96	
		wo	PCT/GB96/01863	1/8/96	Ţ
		EP	96925906.8	1/8/96	
i		GB	9801317.0	1/8/96	15/3/00
		GB/D	9914298.6	1/8/96	15/3/00
		KR	98-700758	1/8/96	
		JP	508214/97	1/8/96	ļ
	Now U.S.P. 6,322,895	us	09/000258	30/1/98	27/11/01
	issued Nov. 27, 2001	US/D	09/964361	28/9/01	1
		CA	2228426	1/8/96	
045 0000		00/0	0000000	4714100	
01P 2638	Silicon Micromineral Tablets	GB/P	9808052.6	17/4/98	
}		WO	PCT/GB99/01185	16/4/99	1
		EP	99918102.7	16/4/99	1
		JP	2000-544305	16/4/99	Į
		NZ	507353	16/4/99	{
		KR	10-2000-7011494	16/4/99	ļ
}		AU	36146/99	16/4/99	1
		CA	2328996	16/4/99	}
)		CN	99807447.0	16/4/99	Į
		US	09/647599	10/3/00	
		HK	01108245.5	22/11/01	ļ
01P 2703	Transferring materials into cells and a	GB/P	9815819.9	22/7/98	
	microneedle array	WO	PCT/GB99/02383	22/7/99	
		EP	99934933.5	22/7/99	
		EP/D	Not yet received	22/7/99	j
		AU	50554/99	22/7/99	ļ
		CA	2337331	22/7/99	İ
		CN	99809028.X	22/7/99	ĺ
		JP	2000-561286	22/7/99	
		KR	2001-7001028	22/7/99	1
		NZ	509142	22/7/99	j
		บร	09/743447	10/1/01	1
		HK	02100735.8	22/7/99	
01P 2831	Derivatized porous silicon	GB/P1	9909996.2	4/5/99	
011 2001	Deliver person officer	GB/P2	0005707.5	13/3/00	
		wo	PCT/GB00/01450	27/4/ 00	<u> </u>
		EP	00925461.6	27/4/ 00	
		CA	Not yet received	274/00	
		CN	00809693.7	27/4/00	[
		JP	2000-615073	274/00	
,		KR	10-2001-70139	27/4/00	1
		NZ	515189	27/4/00	
!	ſ	112	0.0103	277-700	ſ

I certify this to be a true copy of the original. Farnbor

(Scotla	and)		US	09/959318	31/10/01	
oùgh, l	lants		AU	44186/00	27/4/00	
· · ·						
01P 2962	Dharman suting I wand upto and	d	GB/P	9924334.7	45/40/00	
UIP 2962	Pharmaceutical products and	i methods of		1	15/10/99	
	fabrication therefor		WO	PCT/GB00/03894	11/10/00	
			EP	00968068.7	11/10/00	
					1	
01P 2975	Bonded products and metho	ds of	GB/P	9929521.4	16/12/99	
	fabrication therefor		WO	PCT/GB00/04552	30/11/00	
· · · · · · · · · · · · · · · · ·			EP	00979784.6	30/11/00	
01P 2970	Orally Administrable Pharma	ceutical	GB/P	9928511.6	3/12/99	
	product and method of fabica		WO	PCT/GB00/04378	20/11/00	
	U.S. Serial No. 10/		EP	00976163.6	20/11/00	
	Filed: October 2	28, 2002				
01P 3140	Microprojectile Delivery Syste	em	GB/P	0008494.7	7/4/00	
			WO	PCT/GB01/01510	5/4//01	
01P 3166	Dermatological Composition		GB/P	0020276.2	18/8/00	ł
011 0100	Dermatological Composition		wo	PCT/GB01/03633	15/8/01	
					1	
01P 3151	Orthopaedic Implant		GB/P	0014079.8	12/6/00	
			WO	PCT/GB01/02524	8/6/01	
			EP	01940713.9	8/6/01	

The suffixes "P", "P1", "P2", and "P3" indicate that the application is a priority application.

The suffix "D" indicates that the application or patent has been divided from another application or patent in the list.



SCHEDULE 2

KNOW HOW

NON-PATENT INTELLECTUAL PROPERTY

Invention Reports relating to Biosilicon

1	Bioactive silicon	9 th December 1994
	Silicon Micromineral tablets	21 st January 1997
	Si Chip based drug reservoirs	24 th January 1997
	DNA Transfer into cells using micromachining and	
••	Porous silicon technology	2 nd May 1997
5	Nanowelding of silicon	24 th July 1997
	Power source for implanted biosensors	29 th July 1997
	Fabrication of silicon microneedles	31 st October 1997
	Micromachined resorbable Si tablets for	
٠.	Sustained drug delivery	6 th November 1997
9.	Implanted optical spectrometers	10 th November 1997
	Technique for non invasive measurement of blood	j
	Metabolite concentrations	11 th November 1997
11	Silica microcuvettes and shaped needles	19 th November 1997
	Enteric silicon tablets	12 th February 1998
	Silicon microtags for pharmaceutical capsules	·
	and tablets	17 th February 1998
14	.Centrifugally assisted creation of 3D ordered	•
	Si-Si0 ₂ structures	1st April 1998
15	Porous silicon based scaffolds for tissue engineer	ing 9 th April 1998
	Porous multilayer mirrors for in-vivo diagnostics	
	and therapeutics	30 th September 1998
17	In-vivo applications of derivitized mesoporous silic	on 10 th March 1999
18	Resorbable silicon particles for drug delivery	
	via biolistic approaches	9 th February 2000
19	PSi containing ointments lotions and creams	6 [™] March 2000
20	Porous Si based skin patches	8 th March 2000

Biosilicon Laboratory Notebooks

12

194 Novel Si Devices 420 Novel Si Devices	16 March 94 12 April 95
ER3-580 Novel Si Devices	9 November 95
ER3-643 Novel Si Devices	4 March 96
NTD- 15 Novel Si Devices	25 June 96
NTD 25 Novel Si Devices	14 October 96
NTD 29 Novel Si Devices	29 November 96
NTD 35 Novel Si Devices	5 March 97
NTD 56 BioSilicon	12 June 97

NTD 64 BioSilicon NTD 68 BioSilicon NTD 74 BioSilicon EOMC 10 BioSilicon EOMC 19 BioSilicon **EOMC 23 BioSilicon** SSD/MM/20 BioSilicon SSD/MM/83 BioSilicon MMS/MM/15

15 September 97 28 November 97 26 February 98 12 June 98 6 October 98 3 February 99 1 September 99 14 February 00 30-08-00

Biosilicon DERA Reports

1. UK Medical Research Charities

Feb 96

Sources of UK Finance to progress ventures in the medical sector

June 97

3. The potential for biosilicon in animal implants

Oct 97

4. Implanted neuro-interfacing devices

Feb 98

Novel drug delivery

Sept 98

BioSilicon in healthcare

March 99

BioSilicon related Databases

Porous Silicon Publications (1956-2000) – 20 files Nano-Silicon Publications (1985-2000) - 7 files Silicon Biochemistry Publications (1924-2000)—6 files Biomedical Applications of Si Technology - 1 file BIOMEMS Research Groups - 4 files

Market Overviews : commercial reports

- Automated and Miniaturised Medical Diagnostics
- 2. Biomaterial based products
- Cancer Diagnostics and Therapeutics
- 4. Defilbrillator and Pacemakers
- 5. Diabetes Diagnostics and Insulin Delivery
- 6. Drug Delivery and Needleless Technology
- 7. Drug Delivery systems
- 8. Endoscopes
- 9. Gene and Cellular Therapy
- 10. Generic/Drugs
- 11. Minimally Invasive Technologies
- 12. Orthopaedics
- 13. Osteoporosis
- 14. Microelectronic Medical Implants
- 15. Micronutrients, vitamins, minerals and neutraceuticals
- 16. Soft Tissue Implants
- 17. Surgical Tissue Implants
- 18. Vaccines

I certify this to be a true copy of the original.

Jonathan Trapp

Solicitor (Scotland) Farnborough, Hants

13

Company Profiles: Commercial Reports

- 1. Cancer Diagnostics and Therapeutics
- 2. Medical Devices and Diagnostics
- 3. Medtronic
- 4. Orthopaedics
- 5. Orthopaedic Tissue Implants
- 6. Soft Tissue Implants
- 7. Wound Care

I certify this to be a true copy of the original.

Jonathan Trapple Solicitor (Scotland)
Farnborough, Hants

Patent Searches and databases

Biomedical Patents

Biomedical Applications of Silicon Technology: Patents

Porous Silicon: Patents

Publications

- 1. BIOACTIVE SILICON STRUCTURE FABRICATION THROUGH NANOETCHING TECHNIQUES. L T Canham, Adv Mater 7, 1033-1037 (1995)
- 2. APATITE NUCLEATION ON LOW POROSITY SILICON IN ACELLULAR SIMULATED BODY FLUIDS. L T Canham, C L Reeves in MRS Proc Vol 414, 189-194 (1996)
- 3. THE EFFECTS OF DC ELECTRIC CURRENTS ON THE IN-VITRO CALCIFICATION OF BIOACTIVE SILICON WAFERS. L T Canham, J P Newey, C L Reeves, M R Houlton, A Loni, A J Simons, T I Cox. Adv Mater 8, 846 (1996)
- 4. BIOACTIVE POLYCRYSTALLINE SILICON. L T Canham, C L Reeves, D O King, P J Branfield, J G Crabb, M C L Ward. Adv Mater 8, 850 (1996)
- 5. CALCIUM PHOSPHATE NUCLEATION OF POROUS SILICON: FACTORS INFLUENCING KINETICS IN ACELLULAR SIMULATED BODY FLUIDS. L T Canham, C L Reeves, A Loni, M R Houlton, J P Newey, A J Simons, T I Cox. Thin Sol Films Vol 297, 304-307 (1997)
- SILICON AS AN ACTIVE BIOMATERIAL. L T Canham, C L Reeves, D J Wallis, J P Newey, M R Houlton, G J Sapford, R E Godfrey, A Loni, A J Simons, T I Cox, M C L Ward, MRS Proc Vol 452, 579-590 (1997)
- 7. BIOMEDICAL APPLICATIONS OF POROUS SILICON EMIS Datareview 12.5 in Properties of Porous Silicon (IEE 1997), p371-376.
- 8. ASSESSMENT OF THE BIOCOMPATIBILITY OF BULK AND POROUS SILICON AT A SUBCUTANEOUS SITE IN THE GUINEA PIG. A P Bowditch, K

14

65/n/270 -06/03/02

- Waters, H Gale, P Rice, E A M Scott, L T Canham, C L Reeves, T I Cox. To be submitted (2000)
- 9. IN-VIVO ASSESSMENT OF TISSUE COMPATABILITY AND CALCIFICATION OF BULK AND POROUS SILICON. A P Bowditch, K Waters, H Gale, P Rice, E A M Scott, L T Canham, C L Reeves, A Loni, T I Cox. MRS Proc. Vol 536, 149-154 (1999)
- 10. MORPHOLOGICAL CHANGES (INCLUDING FILAMENTATION) ESCHERICHIA COLI GROWN UNDER STARVATION CONDITIONS ON SILICON WAFERS AND OTHER SURFACES. M Wainwright, L T Canham, K Al Waieeh, C L Reeves, Lett Appl. Microbiol. 29,224-227 (1999)
- 11 DERIVATIZED MESOPOROUS SILICON WITH DRAMATICALLY IMPROVED STABILITY IN SIMULATED HUMAN BLOOD PLASMA. L T Canham, C L Reeves, J P Newey, M R Houlton, T I Cox, J M Buriak, M P Stewart. Adv Mater. 11,1505-7 (1999)
- 12. LEWIS ACID MEDIATED HYDROSILYLATION ON POROUS SILICON SURFACES. J M Buriak, M P Stewart, T W Geders, M J Allen, H C Choi, J Smith, D Raftery, L T Canham, J Am Chem. Soc. 121,11491-11502 (1999)
- 13.IN VITRO EVIDENCE FOR CYTOTOXICITY OF POROUS SILICON, STERILIZED BY DRY HEAT. C J Brown, P V Hatton, L T Canham, I M Brook. Submitted to the World Biomaterials Congress 2000
- CHARACTERIZATION OF CALCIUM 14. FABRICATION AND PHOSPHATE/POROUS SILICON/SILICON STRUCTURES DOPED WITH PLATINUM ANTI-TUMOR COMPOUNDS. J I Coffer, X Li, J St John, R F Pinizotto, Y Chen, J Newey, L T Canham. Submitted to Fall MRS 1999
- 15. DERIVATIZED POROUS SILICON MIRRORS: IMPLANTABLE OPTICAL COMPONENTS WITH SLOW RESORBABILITY. L T Canham, M Stewart, J M Buriak, C L Reeves, M Anderson, E K Squire, P A Snow. Submitted to Physica Stat.Solidi.
- 16. AUTOCLAVING OF POROUS SILICON WITHIN A HOSPITAL ENVIRONMENT: POTENTIAL BENEFITS AND PROBLEMS. T Jay, L T Canham, K Heald, C L Reeves, R Downing. Submitted to Physica Stat. Solidi.
- SILICON WAFER STRUCTURES IMPREGNATED WITH 17. POROSIFIED COMPOUNDS FABRICATION. ANTITUMOR PLATINUM CHARACTERIZATION AND DIFFUSION STUDIES. X Li, J St John, J L Coffer, Y Chen, R F Pinozotto, J Newey, C L Reeves, L T Canham. Submitted to J Biomed.Microdevices.

I certify this to be a true copy of the original. Varatha. 1,00 Jonathan Trapp Solicitor (Scotland)

Farnborough, Hants

15

65/n/270 -06/03/02

SCHEDULE 3

Domain names

Left intentionally blank

I certify this to be a true copy of the original.

Jonathan Trapp \\\
Solicitor (Scotland)
Farnborough, Hants

16

65/n/270 -06/03/02

SCHEDULE 4

Trade Marks

Left Intentionally blank

I certify this to be a true copy

of the original.

Jonathan Trapp Solicitor (Scotland) Farnborough, Hants

17

PATENT REEL: 013438 FRAME: 0724

RECORDED: 10/29/2002